Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) will present new long-term clinical data on a transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma at ECIO 2026 in Basel, April 26–30, 2026.
The oral presentation (Abstract No. 350) titled “Pain mitigation in pancreatic adenocarcinoma: a long-term analysis of denervation via transvascular RF energy-based ablation” will be delivered by Nikola Cesarovic, PhD, on April 29, 2026, 8:30–10:00 AM (Europe/Zurich), highlighting long-term outcomes from the company’s ongoing clinical evaluation of its minimally invasive, transvascular RF energy-based approach.
Positive
- None.
Negative
- None.
News Market Reaction – AMIX
On the day this news was published, AMIX declined 2.30%, reflecting a moderate negative market reaction. Argus tracked a trough of -10.9% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $102K from the company's valuation, bringing the market cap to $4.32M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AMIX is down 5.4% while momentum scans show only one peer (MOVE) also moving down (-2.65%). Other tracked peers show mixed or flat moves, indicating today’s weakness is more stock-specific than a broad medical device trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 08 | Conference selection | Positive | +4.5% | Featured abstract and podium presentation for long-term pancreatic cancer pain data at SIR 2026. |
| Mar 11 | Investor conference slot | Positive | +0.3% | Management presenting at LSI USA ’26 with investor meetings, enhancing institutional visibility. |
| Mar 05 | Innovation competition | Positive | +2.2% | Selection for CRT 2026 Best Innovation Competition highlighting transvascular nerve-targeted technology. |
| Mar 04 | Clinical podium data | Positive | +3.1% | Top Abstract at CRT 2026 for clinical feasibility and outcomes of transvascular RF nerve neurolysis. |
| Feb 25 | Strategic update | Positive | +8.0% | CEO Corner segment outlining publication strategy and push for peer-reviewed validation. |
Recent conference and visibility news has generally coincided with modest positive price reactions for AMIX.
Over the past few months, AMIX has repeatedly highlighted its nerve-targeted RF technology through scientific forums. In February 2026, a CEO Corner segment outlined a broader publication strategy. In March 2026, the company reported multiple podium and competition selections at CRT 2026, followed by a presentation announcement for LSI USA ’26 on March 11. On April 8, 2026, similar long‑term pain mitigation data in pancreatic cancer was featured at SIR 2026, which saw a positive price reaction. Today’s ECIO presentation continues this visibility trajectory.
Regulatory & Risk Context
An effective S-3 shelf dated Nov 26, 2025 registers 13,504,998 warrant shares for resale. While resale proceeds go to the selling holder, Autonomix could receive up to $7.7 million in gross proceeds if all Common Warrants are exercised in cash at $0.8607 per share, and full exercise would significantly increase shares outstanding.
Market Pulse Summary
This announcement extends Autonomix’s strategy of showcasing its minimally invasive, nerve-targeted RF ablation platform across major oncology forums. The ECIO 2026 oral presentation on long-term pain mitigation in pancreatic adenocarcinoma follows similar podium selections in early 2026, reinforcing clinical visibility. Investors may track future publications, additional long-term outcomes, and how ongoing financing tools, including the S-3 warrant resale capacity of up to $7.7 million, interact with the company’s path toward commercialization.
Key Terms
transvascular radiofrequency (rf) ablation medical
pancreatic adenocarcinoma medical
denervation medical
rf energy-based ablation medical
interventional oncology medical
oral presentation technical
AI-generated analysis. Not financial advice.
THE WOODLANDS, TX, April 22, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that new long-term clinical data evaluating its transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma will be presented at the European Conference on Interventional Oncology (ECIO) 2026 being held April 26 – 30, 2026 in Basel CH.
The presentation, titled “Pain mitigation in pancreatic adenocarcinoma: a long-term analysis of denervation via transvascular RF energy-based ablation” (Abstract No. 350), has been accepted as an oral presentation in the session “Y90 and Novel Therapies.”
The presentation will be delivered by Nikola Cesarovic, PhD, on Wednesday, April 29, 2026, from 8:30 AM to 10:00 AM (Europe/Zurich), and will highlight long-term outcomes from the Company’s ongoing clinical evaluation of its minimally invasive, transvascular RF energy-based approach.
Pancreatic cancer is often associated with severe, difficult-to-manage pain, representing a significant unmet medical need. Autonomix’s proprietary technology is designed to selectively target and ablate relevant nerves via the vascular system, with the potential to provide meaningful and durable pain relief while improving patient quality of life.
The ECIO Annual Meeting convenes leading interventional oncologists and healthcare professionals to showcase advances in image-guided cancer therapies and emerging treatment technologies. For more information, please visit ecio.org.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
